## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.64 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (57% of avg), momentum weakening (-2.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($96.45)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Is Revvity's Share Price Rally Justified After Recent Partnerships and Acquisitions?**
- Source: Simply Wall Street | 20251129T233228 | Neutral | Relevance: 98%
- Revvity's share price has rallied recently, bouncing back from a yearly low, driven by new partnerships, product launches, and acquisitions. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 18.9% at $128.71, while a Price-to-Earnings (PE) ratio comparison with its "Fair Ratio" indicates it might be overvalued on an earnings basis. The article encourages investors to use "Narratives" to incorporate qualitative factors into their valuation decisions.

**2. (RVTY) Movement as an Input in Quant Signal Sets**
- Source: Stock Traders Daily | 20251130T175600 | Neutral | Relevance: 98%
- This article analyzes Revvity Inc. (NASDAQ: RVTY) using AI-generated quant signal sets, highlighting a strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis. The report details support and resistance levels for different time horizons and offers access to real-time signals and personalized dashboard features.

**3. Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?**
- Source: MSN | 20251129T145146 | Neutral | Relevance: 97%
- Revvity (RVTY) has seen a 9.5% increase in its stock price since its last earnings report, outperforming the S&P 500's 5% gain. The article discusses analyst expectations for its upcoming earnings, highlighting key metrics like EPS and revenue, and considers fundamental and technical factors that could influence its future performance as it approaches its next report on May 7, 2024.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Elevated short interest (9.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- M&A activity or partnership announcements may unlock value.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.64 indicates undervaluation relative to growth. Forward P/E 19.3x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.0B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.64 |
| Forward P/E | 19.3 |
| Current P/E | 20.8 |
| YoY Growth | 7.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.8% to 6.1% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 (-1.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 7.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.12), confirming momentum. Volume at 57% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.08% (CS: 94) | Strong |
| RSI_14 | 63.2 | Neutral |
| MACD Histogram | 1.12 | Bullish |
| vs SMA20 | 1.072x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.069x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $102.43
- **Stop Loss:** $96.45 (5.8% risk)
- **Target:** $114.39 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 125
- **Position Value:** $12,803.75
- **Portfolio %:** 12.80%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*